PDCD1 and melanoma: A clinical trial designed to study whether anti-PD-1 resistance may be surmounted by altering the intestinal microbiota, analyzed the safety and efficiency of responder-derived fecal microbiota transplantation (FMT) along with anti-PD-1 in patients with PD-1-refractory melanoma.